65,437 trials
Hepatitis B · Chronic Hepatitis B Atypical
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%) — 5; 6; 2; 3 Participants
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Body Fat Disorder
Primary: Proportion of Correctly Identified Photos by Blinded Reviewers — 28 photos
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Advanced Malignancies
Primary: Number of Participants With Adverse Events (AEs) - Carbiralizumab Monotherapy — 3; 4 Number of participants
Asthma
Primary: Number of Participants With Cardiac Arrhythmias — 11; 17; 102; 16 Participants
Essential Hypertension
Primary: Percentage of Patients With Controlled Blood Pressure (<140/90 mmHg) — 3083 Participants
Duchenne Muscular Dystrophy
Primary: Baseline for the North Star Ambulatory Assessment (NSAA) Total Score — 23.1; 24.5; 22.7 score on a scale
Intraocular Pressure · Corneal Opacity
Primary: Change in Intraocular Pressure (IOP) From Baseline Through Month 3 — 14.38; 14.30; 13.67; 13.28 mmHg
Coronary Artery Bypass Graft · Non-cardiac Thoracic Surgery · Frailty
Primary: Recruitment Rate — 35 Participants
Metastatic Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of Dose of PD-1 Knockout T Cells Using Common…
Fabry Disease
Primary: Number Of Participants Experiencing Adverse Events (AEs) — 80; 26; 1; 0 Participants
Stage I Papillary Thyroid Cancer · Stage II Papillary Thyroid Cancer · Stage III Papillary Thyroid Cancer
Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Cancer
Primary: Overall Survival — 1704 Participants